Literature DB >> 14604889

Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells.

Maria M Simile1, Maria R De Miglio, Maria R Muroni, Maddalena Frau, Giuseppina Asara, Silvia Serra, Maria D Muntoni, Maria A Seddaiu, Lucia Daino, Francesco Feo, Rosa M Pascale.   

Abstract

A number of genetic interactions are involved in the control of cell cycle, but their role and nature have not been completely clarified. The knowledge of the behavior of these interactions in hepatocellular carcinoma, could optimize preventive and therapeutic strategies based on cell cycle restraint. We studied downstream events following c-MYC and CYCLIN D1 gene inhibition, by lipoplex-delivered MYC and CYCLIN D1 antisense oligodeoxy nucleotides (aODNM, aODND1), in in vitro cultured human HepG2 and rat Morris 5123 hepatoma cells. 0.5-20 micro M aODN(M) and aODND1 inhibited in vitro growth of both cell types. Scramble oligomer (SCR) and sense ODNs had no or relatively poor effect. Ten micromolar aODNM and aODND1, but not SCR, also induced a significant increase in the apoptotic index of HepG2 and 5123 cells, and inhibited colony formation in soft agar by HepG2 cells. Treatment of the cells with aODNM plus aODND1 had no additive effect on growth and apoptosis. aODNM and aODND1 induced >50% decrease in c-MYC and CYCLIN D1 gene expression, respectively, at both mRNA and protein level. The inhibition of gene expression by aODNs was highly specific, and SCR was without effect. The reduction in c-MYC and CYCLIN D1 expression by aODNs, was associated with a >50% decrease in E2F1 mRNA and protein production, without changes in CYCLIN A and CYCLIN E expression. These results suggest the involvement of both c-MYC and CYCLIN D1 on E2F1 gene function, and indicate that aODNM and aODND1 may inhibit hepatoma cell growth through down-regulation of the E2F1 gene. The inhibition of E2F1 gene expression by E2F1 aODN, was associated with strong growth restraint of HepG2 cells. Thus, interactions of c-MYC and CYCLIN D1 with E2F1 gene are essential for cell cycle activity in hepatoma cells, and their inhibition may have a therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604889     DOI: 10.1093/carcin/bgh014

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  32 in total

1.  Inhibition of human lens epithelial B-3 cell proliferation by adenovirus-mediated transfer of antisense c-myc construct.

Authors:  Jie Sun; Lixin Xie; Yao Wang; Ting Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-01-26       Impact factor: 3.117

2.  Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice.

Authors:  Jyoti Srivastava; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Devaraja Rajasekaran; Chadia L Robertson; Mark A Subler; Jolene J Windle; Catherine I Dumur; Nitai D Mukhopadhyay; Dawn Garcia; Zhao Lai; Yidong Chen; Uthra Balaji; Paul B Fisher; Devanand Sarkar
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

3.  MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1~let-7d via noncanonical E-box.

Authors:  Zifeng Wang; Sheng Lin; Julia Jun Li; Zhenhua Xu; Hong Yao; Xiao Zhu; Dan Xie; Zan Shen; Johnny Sze; Kui Li; Gang Lu; Danny Tat-Ming Chan; Wai Sang Poon; Hsiang-fu Kung; Marie Chia-mi Lin
Journal:  J Biol Chem       Date:  2011-09-08       Impact factor: 5.157

4.  An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis.

Authors:  Maddalena Frau; Maria M Simile; Maria L Tomasi; Maria I Demartis; Lucia Daino; Maria A Seddaiu; Stefania Brozzetti; Claudio F Feo; Giovanni Massarelli; Giuliana Solinas; Francesco Feo; Ju-Seog Lee; Rosa M Pascale
Journal:  Cell Oncol (Dordr)       Date:  2012-03-21       Impact factor: 6.730

5.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Konstantinos Evangelou; Sophia Havaki; Athanassios Kotsinas
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  F-box protein Skp2: a novel transcriptional target of E2F.

Authors:  L Zhang; C Wang
Journal:  Oncogene       Date:  2006-04-27       Impact factor: 9.867

7.  Targeting c-Myc as a novel approach for hepatocellular carcinoma.

Authors:  Che-Pin Lin; Chien-Ru Liu; Chun-Nin Lee; Tze-Sian Chan; H Eugene Liu
Journal:  World J Hepatol       Date:  2010-01-27

8.  Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells.

Authors:  Thippeswamy Gulappa; Ramadevi Subramani Reddy; Suman Suman; Alice M Nyakeriga; Chendil Damodaran
Journal:  Cancer Lett       Date:  2013-05-16       Impact factor: 8.679

9.  Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells.

Authors:  Li-Jun Yu; Mo-Li Wu; Hong Li; Xiao-Yan Chen; Qian Wang; Yuan Sun; Qing-You Kong; Jia Liu
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

10.  Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter.

Authors:  Wendy W Hwang-Verslues; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2007-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.